evipedia.ai
← Back

Strontium for Health & Longevity

Evidence Review created on 07/31/2026 using AI4L / Opus 4.8

Also known as: Strontium Ranelate, Strontium Citrate, Strontium Chloride, Strontium Carbonate, Strontium Gluconate, Sr, Protelos, Protos, Osseor

Motivation

Strontium is a mineral that sits directly below calcium on the periodic table and behaves much like it in the body, where roughly 99 percent of what is absorbed ends up in bone. Because of this close chemical kinship, strontium has long been studied as a way to make aging bones denser and less prone to breaking, and it is sold both as an over-the-counter supplement and, in some countries, as a prescription bone drug.

Interest in strontium grew after large studies in older women reported fewer spine fractures, and it became widely used in Europe for severe bone loss before safety questions narrowed its role. Outside the prescription setting, a similar-looking supplement form is marketed for bone strength, though it has been tested far less. This gap between a heavily studied drug and a lightly studied supplement is central to how strontium is understood today.

This review examines what strontium is, how it may strengthen bone, the strength of the evidence for its benefits, and the safety concerns that have shaped its use, so that the trade-offs involved can be weighed clearly rather than assumed.

Benefits - Risks - Protocol - Conclusion

This section lists high-level overviews that introduce strontium, its mechanism, and the debate over its bone benefits and safety.

Grokipedia

  • Strontium

    The dedicated Grokipedia article on the element, covering its chemistry, biological similarity to calcium, medical use in bone disease, and safety profile in a single reference page.

Examine

  • Strontium

    Examine’s independent, research-graded summary of strontium supplementation, covering the common citrate form, dosing ranges, the evidence for bone health, and tolerability.

ConsumerLab

No dedicated ConsumerLab review article exists for strontium as a standalone intervention. Strontium is addressed only within ConsumerLab’s broader Osteoporosis and Bone Health supplement coverage and a cardiovascular safety alert, so no primary strontium page is available to link.

Systematic Reviews

The following systematic reviews and meta-analyses summarize the fracture, bone-density, and comparative-safety evidence for strontium in osteoporosis.

Mechanism of Action

Strontium is an alkaline-earth metal chemically similar to calcium, and after oral intake it distributes almost entirely to the skeleton, where it substitutes for a small fraction of calcium in the mineral crystal and adsorbs onto bone surfaces.

Its central proposed mechanism is a “dual” or uncoupling effect on bone remodeling: in laboratory and animal models strontium appears to stimulate the bone-forming cells (osteoblasts) while simultaneously reducing the activity and lifespan of the bone-resorbing cells (osteoclasts). This is unusual, because most bone drugs do only one or the other.

At the molecular level, strontium is thought to act largely through the calcium-sensing receptor (CaSR, a cell-surface protein that detects calcium-like ions). Activation of this receptor in bone-forming cells promotes their replication and survival, while strontium also shifts the balance of the osteoprotegerin/RANKL system (a signaling pair that controls how many bone-resorbing cells mature) toward less resorption.

A competing and important mechanistic caveat exists. Because strontium has a much higher atomic weight than calcium, its presence in bone increases the signal measured by dual-energy X-ray absorptiometry (DXA, the standard bone-density scan). A meaningful part of the apparent rise in bone mineral density (BMD, a measure of mineral packed into bone) on a scan therefore reflects strontium’s physical density rather than true new bone, and correction factors suggest only roughly half of the measured gain represents genuine bone. Some analyses of bone-quality markers (Sharma et al., 2024) found no measurable improvement in the material properties of bone, which argues against a large true anabolic effect and keeps the mechanism partly contested.

As a mineral rather than a conventional small-molecule drug, strontium has no cytochrome-P450 (liver-enzyme) metabolism; it is not metabolized, is handled like calcium, and is cleared by the kidneys with a long skeletal retention time.

Historical Context & Evolution

Strontium’s original scientific interest was twofold and often confused in the public mind. Non-radioactive (stable) strontium was studied from the 1950s onward as a bone-seeking mineral, while the radioactive isotope strontium-90 from nuclear fallout became infamous as a bone hazard. The two are chemically similar but entirely different in effect, and stable strontium salts were explored as bone therapies precisely because the element concentrates in the skeleton.

Early mid-20th-century reports, including small studies using strontium lactate, suggested improvements in bone pain and density, but the work was limited and largely set aside. Interest revived in the 1990s when a French pharmaceutical program developed strontium ranelate, pairing two strontium atoms with ranelic acid to improve absorption, and ran the large SOTI and TROPOS fracture trials that led to European approval in 2004.

The reasons strontium came to be considered for health optimization follow from this history: it was a comparatively inexpensive, orally active agent that raised bone-density readings and reduced spine fractures, and it appeared to build bone rather than only slow its loss, which was attractive for aging skeletons.

The evolution of opinion has been substantial but is not a closed book. After approval, pooled safety data linked strontium ranelate to blood clots, rare but severe hypersensitivity reactions, and a possible excess of heart attacks, prompting European regulators in 2013–2014 to restrict it to severe osteoporosis in people without cardiovascular disease, and the manufacturer later discontinued the branded product. Critics argued the fracture benefit was modest and the density gains partly artefactual, while defenders and later real-world analyses questioned whether the heart-attack signal was real or a product of confounding. Generic strontium ranelate remains available in some markets, and the supplement form persists, so the current standing is better described as narrowed and cautious rather than settled.

Expected Benefits

The benefits below are framed for a proactive, risk-aware reader weighing strontium against other bone strategies, not as population screening advice. The strongest evidence concerns the prescription salt strontium ranelate in postmenopausal women; benefits of over-the-counter strontium citrate are extrapolated and weaker.

High 🟩 🟩 🟩

Reduction of Spinal (Vertebral) Fractures

The best-established benefit is a reduction in new spine fractures with strontium ranelate. In the pivotal three-year trials and the Cochrane meta-analysis of randomized controlled trials (studies that randomly assign treatment to limit bias), 2 grams daily reduced new vertebral fractures by roughly 37–41 percent versus placebo in postmenopausal women with osteoporosis. The effect is consistent across pooled analyses and did not depend strongly on baseline fracture risk, though it applies to the ranelate salt at a specific dose and not clearly to supplement forms.

Magnitude: Relative risk 0.63 (about a 37% reduction) for new vertebral fractures over 3 years; roughly 40% in the SOTI trial (relative risk 0.59).

Increased Bone Mineral Density Readings

Strontium reliably raises measured bone mineral density at the spine and hip, typically by several percent per year, and it ranked first for spine density gains in a Bayesian network meta-analysis. This benefit is genuine as a measurement but must be read with caution: because strontium is physically denser than calcium, a substantial portion of the scan increase reflects the element itself rather than new bone, so true structural gain is smaller than the number suggests.

Magnitude: Spine BMD increases of roughly 6–14% over 3 years on DXA, of which correction factors suggest only about half represents true bone.

Medium 🟩 🟩

Reduction of Non-Vertebral Fractures

Strontium ranelate produced a smaller, borderline-significant reduction in fractures outside the spine (wrist, hip, and other sites). The effect is real in pooled trial data but modest and less robust than the spine benefit, and network comparisons place strontium below bone-forming agents and several bisphosphonates for these fractures.

Magnitude: Relative risk about 0.86 (roughly a 14% reduction) for all non-vertebral fractures over 3 years.

Low 🟩

Hip Fracture Reduction in the Highest-Risk Elderly

A reduction in hip fractures specifically was seen only in a post-hoc subgroup of the TROPOS trial (women aged 74 and older with very low femoral-neck density), not in the trial as a whole, which was not designed to test hip fractures. The signal is encouraging but rests on a secondary analysis and should be treated as suggestive rather than proven.

Magnitude: About a 36% relative reduction in hip fracture in the high-risk subgroup (relative risk 0.64); not significant in the overall trial population.

Symptom Relief in Knee Osteoarthritis

A separate randomized trial (SEKOIA) of strontium ranelate in knee osteoarthritis reported slowed joint-space narrowing and modest symptom improvement, hinting at a cartilage effect. Evidence is limited to this setting, was not the drug’s licensed use, and the clinical importance of the structural change is uncertain.

Magnitude: Roughly 0.1 mm/year less joint-space narrowing versus placebo over 3 years; small symptom benefit.

Speculative 🟨

Dental Remineralization and Tooth Sensitivity

Strontium salts (notably strontium chloride and strontium acetate) are used in toothpastes for sensitivity, and strontium-containing bioactive glasses are being tested for enamel and dentine repair. For systemic supplementation, any general dental or “healthy-aging” benefit beyond local products is unproven and rests on mechanism and analogy to calcium rather than controlled outcome trials.

Benefit-Modifying Factors

  • Baseline bone density and fracture risk: The absolute benefit is largest in those with established osteoporosis and prior fractures; someone with only mild bone loss stands to gain far less in real fracture terms, even if their density reading rises.

  • Baseline calcium and vitamin D status: Strontium was always studied on a background of adequate calcium and vitamin D, and deficiency in either is expected to blunt bone benefit; the two minerals also compete for absorption, so timing matters.

  • Sex differences: Nearly all fracture evidence is in postmenopausal women. A smaller study in men with osteoporosis showed density changes similar to women, but fracture benefit in men is inferred rather than directly demonstrated.

  • Age: Benefit has been shown into advanced age (including women 80 and older), which distinguishes strontium from some agents; however, older age also raises the competing clotting and cardiovascular risks that limit its use.

  • Pre-existing bone-turnover state: Analyses suggest anti-fracture efficacy is broadly present across different baseline bone-turnover levels, so high or low turnover is not a strong selector for or against benefit.

  • Genetic polymorphisms: No well-validated genetic variant is established to predict strontium response; variation in the calcium-sensing receptor gene is biologically plausible but not clinically actionable, so genotype is not currently a useful guide.

Potential Risks & Side Effects

Risks below are framed for an individual weighing strontium personally. The most serious concerns come from prescription-dose strontium ranelate and were central to its regulatory restriction; supplement-dose citrate is less studied, which is itself a source of uncertainty rather than reassurance.

High 🟥 🟥 🟥

Venous Thromboembolism (Blood Clots)

Strontium ranelate is consistently associated with an increased risk of venous thromboembolism (VTE, clots in the deep veins or lungs). This appeared in the pooled trial safety data and was confirmed in large multi-country real-world analyses, and it is the most reproducible serious harm. The mechanism is not fully understood, and the risk is highest in people already prone to clotting.

Magnitude: Roughly a 1.4-fold increased relative risk in trials; multi-database analysis found about a 25–30% excess of VTE versus bisphosphonates.

Gastrointestinal Effects (Diarrhea and Nausea)

The most common day-to-day side effects are diarrhea and nausea, seen clearly in randomized trials against placebo. These are usually mild and often settle within a few months, but they are the main reason for early discontinuation and are relevant to the supplement forms as well.

Magnitude: Diarrhea in roughly 6–7% versus about 5% on placebo; nausea similarly modestly increased, mostly transient.

Medium 🟥 🟥

Cardiovascular Events (Heart Attack) ⚠️ Conflicted

Whether strontium ranelate raises the risk of heart attack is genuinely contested. A pooled trial analysis reported an excess of myocardial infarction (heart attack), triggering regulatory restriction, and some cohort data suggested increased cardiovascular death. However, several large real-world studies, including a Danish cohort and a five-country database study, found no significant excess of heart attack once confounding was accounted for. The safest reading is that a signal exists and cannot be dismissed, which is why cardiovascular disease is a contraindication.

Magnitude: Trial pooled analysis suggested roughly 1.6-fold odds of heart attack; several cohorts found no significant increase (hazard ratios near 0.9–1.0).

Severe Hypersensitivity Reactions (DRESS)

Strontium ranelate can rarely cause DRESS syndrome (drug reaction with eosinophilia and systemic symptoms, a severe delayed allergic reaction with rash, fever, and internal-organ involvement) and other serious skin reactions. Though very uncommon, these can be life-threatening and typically appear within the first weeks of treatment, warranting immediate discontinuation if a widespread rash develops.

Magnitude: Rare (on the order of 1 in 10,000–20,000 users) but potentially fatal; requires permanent stopping of the drug.

Low 🟥

Misleading Bone-Density Readings

Because strontium inflates the DXA signal, follow-up scans can substantially overstate improvement, potentially giving false reassurance and leading to misinterpretation of treatment success. This is a monitoring hazard rather than a bodily harm, but it can distort clinical decisions if the artefact is not accounted for.

Magnitude: Approximately half of the measured BMD gain may be artefactual attenuation from strontium rather than new bone.

Nervous-System Symptoms (Headache, Memory Complaints)

Trials and the Cochrane review noted a small excess of nervous-system effects such as headache and memory disturbance with 2 grams daily. These are generally mild and reversible, but they were flagged as needing further study and add to the tolerability picture.

Magnitude: Not quantified in available studies.

Speculative 🟨

Unknown Long-Term Safety of Supplement-Dose Citrate

Over-the-counter strontium citrate is often taken at doses delivering elemental strontium comparable to the drug, yet without the trial safety monitoring that revealed the clotting and cardiovascular signals. Any assumption that the citrate form is inherently safer is unproven, and its long-term cardiovascular and skeletal effects remain essentially untested in controlled studies.

Risk-Modifying Factors

  • Personal or family history of clotting: A prior deep-vein clot, pulmonary embolism, or an inherited clotting tendency sharply raises the most established danger and is a reason to avoid strontium entirely.

  • Cardiovascular status: Established or high-risk ischemic heart disease, prior heart attack, peripheral artery disease, cerebrovascular disease, or uncontrolled high blood pressure shift the risk-benefit against strontium and are formal contraindications for the ranelate salt.

  • Immobilization: Temporary immobilization (after surgery or during illness) further increases clot risk, and stopping strontium during such periods is commonly advised.

  • Kidney function: Strontium is cleared by the kidneys, so reduced function (for example an estimated glomerular filtration rate, a measure of kidney filtering, below 30 mL/min) raises accumulation and is a reason for caution or avoidance.

  • Age and sex: Advanced age increases both clotting and cardiovascular vulnerability; the safety data are overwhelmingly in women, leaving men’s risk profile less well characterized.

  • Genetic polymorphisms: No validated genetic test predicts serious strontium harm; hypersensitivity reactions such as DRESS have been linked to immune-related HLA gene patterns for other drugs, but no actionable strontium-specific marker is established.

Key Interactions & Contraindications

  • Calcium (supplements, dairy, fortified foods): Calcium competes directly with strontium for absorption. Severity: caution (reduced efficacy). Consequence: markedly lower strontium uptake. Mitigation: separate strontium from calcium-containing food or supplements by at least 2 hours, typically dosing strontium at bedtime away from meals.

  • Quinolone and tetracycline antibiotics (ciprofloxacin, levofloxacin, doxycycline, tetracycline): Strontium, like calcium, binds these drugs in the gut. Severity: caution to avoid concurrent dosing. Consequence: reduced antibiotic absorption and possible treatment failure. Mitigation: separate dosing by at least 2 hours, or pause strontium during the antibiotic course.

  • Oral bisphosphonates (alendronate, risedronate) and other bone drugs: Combining strontium with other antiresorptives is not well studied and offers no proven added benefit. Severity: caution. Consequence: uncertain efficacy and confounded density monitoring. Mitigation: avoid routine combination; choose one agent.

  • Antacids and mineral supplements (magnesium, aluminum, zinc, iron): These can reduce strontium absorption through competition or binding. Severity: minor to moderate. Consequence: lower strontium levels. Mitigation: time separation of at least 2 hours.

  • Additive clot-risk agents (combined estrogen-containing hormone therapy, thalidomide-class drugs): Agents that themselves raise clotting risk compound strontium’s thromboembolic danger. Severity: caution. Consequence: increased venous clot risk. Mitigation: avoid combination or monitor closely in those with any clot risk.

  • Populations who should avoid strontium: Current or prior venous thromboembolism; established ischemic heart disease, prior myocardial infarction (particularly recent, within 90 days), peripheral or cerebrovascular disease; uncontrolled hypertension; severe kidney impairment (creatinine clearance below 30 mL/min); pregnancy and breastfeeding; and anyone with a history of severe drug hypersensitivity such as DRESS.

Risk Mitigation Strategies

  • Cardiovascular and clot screening before starting: Because venous clots and possible heart attack are the defining risks, review personal and family clot history, blood pressure, and heart disease before use to exclude those for whom strontium is contraindicated, preventing the most serious harms.

  • Stop promptly for warning signs: To mitigate blood clots and severe hypersensitivity, discontinue immediately and seek care for leg swelling or pain, chest pain or breathlessness, or any widespread rash with fever, especially within the first weeks.

  • Interrupt during immobilization: Pause strontium during periods of prolonged bed rest, hospitalization, or after surgery to reduce the compounded venous-clot risk from immobility.

  • Separate from calcium and interacting drugs: Dose strontium at least 2 hours apart from calcium, antacids, mineral supplements, and quinolone or tetracycline antibiotics to preserve both strontium and drug effectiveness.

  • Interpret DXA scans with a correction mindset: To avoid being misled by inflated density readings, treat on-treatment bone-density gains as partly artefactual (roughly half), and judge success by fracture avoidance and overall trend rather than a single impressive percentage.

  • Maintain adequate calcium and vitamin D: Ensure sufficient (but time-separated) calcium and vitamin D intake so the bone benefit is not blunted by deficiency, targeting typical repletion (for example vitamin D to a 25-hydroxyvitamin D level in the optimal range) before relying on strontium.

Therapeutic Protocol

  • Standard prescription protocol: As used by European bone specialists, strontium ranelate is given as 2 grams once daily of the elemental-equivalent salt, reserved for severe postmenopausal (or male) osteoporosis at high fracture risk in people without cardiovascular contraindications, always on a background of calcium and vitamin D.

  • Supplement (integrative) approach: Integrative and longevity-oriented practitioners more often use strontium citrate, commonly providing 680 mg of elemental strontium daily (the amount closest to the studied dose), positioned as one part of a broader bone program; this approach is popularized in the consumer bone-health literature rather than by trial evidence.

  • Competing approaches without a default: Conventional guidelines generally favor bisphosphonates, denosumab, or bone-forming agents (teriparatide, romosozumab) over strontium, whereas integrative practice retains strontium as an option; both are presented here as choices, not as one being the established standard.

  • Best time of day: Strontium is taken away from food and calcium, so bedtime dosing at least 2 hours after the evening meal is standard to maximize absorption.

  • Half-life and retention: Strontium is not metabolized; its plasma half-life is on the order of 60 hours, but skeletal retention is very long (months to years), which is why benefits and any density artefact persist after stopping.

  • Single versus split dosing: It is taken as a single daily dose; splitting offers no established advantage and complicates the required separation from calcium and meals.

  • Genetic polymorphisms: No pharmacogenetic variant (such as those affecting drug-metabolizing enzymes) is established to guide strontium dosing, since it is a mineral cleared by the kidney rather than enzyme-metabolized.

  • Sex differences: Dosing is the same studied 2 grams (or citrate equivalent) in both sexes; efficacy data are far stronger in women, and response in men is inferred from density rather than fracture trials.

  • Age considerations: Benefit extends into advanced age, but the higher background cardiovascular and clot risk in older adults tightens the requirement to exclude contraindications before use.

  • Baseline biomarkers: Response and safety are considered against baseline bone-density, kidney function, and calcium/vitamin D status, which should be assessed before starting.

  • Pre-existing conditions: Active or prior clotting disease, heart disease, uncontrolled hypertension, and significant kidney impairment redirect the protocol toward avoidance rather than dose adjustment.

Discontinuation & Cycling

  • Long-term versus short-term: Strontium is used as a long-term therapy for as long as high fracture risk persists and benefit outweighs risk; it is not a brief course, though periodic reassessment of continued need is standard.

  • Withdrawal effects: There is no classic withdrawal syndrome, but the anti-fracture benefit is not durable after stopping, and bone turnover returns toward baseline, so protection wanes over time.

  • Tapering: No taper is required; strontium can be stopped outright, and because skeletal retention is long, tissue levels decline slowly on their own.

  • Cycling: Cycling is not established or recommended for strontium; unlike some anabolic bone agents there is no defined on/off schedule, and intermittent use has not been shown to maintain efficacy.

  • Sequencing after stopping: Because benefit is not maintained, discontinuation is generally followed by transition to another bone therapy if fracture risk remains high, a decision made with a clinician and complicated by the lingering density artefact on scans.

Sourcing and Quality

  • Chemical form matters: The trial-proven agent is strontium ranelate (prescription, now often generic); the common supplement is strontium citrate, with other over-the-counter forms including chloride, carbonate, gluconate, and aspartate. These differ in elemental strontium content, so labels should state elemental strontium, not just total salt weight.

  • Elemental dose transparency: Look for products that clearly declare elemental strontium per serving (for example 680 mg), since salt-weight labeling can obscure the true dose relative to the studied amount.

  • Third-party testing: Prefer supplements independently verified for identity, potency, and contaminant limits (for example NSF, USP, or equivalent), because strontium ores can carry trace heavy-metal or radioactive-isotope contamination if poorly sourced.

  • Reputable sources: Established supplement brands (such as those reviewed by independent testers) and, for the prescription salt, licensed pharmacies dispensing generic strontium ranelate where approved, are preferable to unbranded bulk powders of uncertain purity.

  • Avoid radioactive confusion: Reputable products use stable (non-radioactive) strontium; this is standard for commercial supplements, but sourcing from unverified suppliers should be avoided to ensure the stable form and clean contaminant profile.

Practical Considerations

  • Time to effect: Bone-density readings rise within the first year, but meaningful fracture-risk reduction is a multi-year outcome; users should expect a slow benefit measured over 1–3 years, not weeks.

  • Common pitfalls: The most frequent mistakes are taking strontium together with calcium or food (cutting absorption), over-interpreting inflated DXA gains as true bone, and using it despite clot or heart-disease risk factors that should exclude it.

  • Regulatory status: In the United States strontium is sold only as an unregulated dietary supplement, not an approved drug; in parts of Europe generic strontium ranelate remains a restricted prescription medicine after the branded product was withdrawn. Supplement use for osteoporosis is effectively off-label self-treatment.

  • Cost and accessibility: Strontium citrate supplements are inexpensive and widely available online; the prescription salt is harder to obtain and, where available, requires specialist oversight due to the safety restrictions. Because strontium is a low-cost generic or supplement rather than a patented agent, it generates little commercial return compared with costly newer drugs such as romosozumab or teriparatide, so manufacturers have scant incentive to fund large new strontium trials; institutional payers (insurers, national health systems), by contrast, have a financial incentive to favor the cheapest adequate option, and these opposing cost pressures are a potential source of structural bias in both guideline formation and the direction of research funding, independent of the underlying evidence.

Interaction with Foundational Habits

  • Sleep: Interaction is largely indirect. Strontium has no established direct effect on sleep, though bedtime dosing (chosen to avoid calcium and food) is convenient; rare nervous-system side effects such as headache could in principle disturb sleep in sensitive users.

  • Nutrition: Interaction is direct and important. Calcium in food and supplements competes with strontium for absorption, so strontium must be separated from dairy, fortified foods, and calcium supplements by at least 2 hours; adequate calcium, vitamin D, and protein remain the nutritional foundation on which any strontium benefit is built.

  • Exercise: Interaction is potentiating and indirect. Mechanical loading from resistance and impact exercise is the most evidence-backed stimulus for bone and complements strontium’s proposed bone-forming action; there is no evidence strontium blunts training adaptations, and exercise should be regarded as the primary bone intervention with strontium as an adjunct.

  • Stress management: Interaction is indirect. Chronic stress and elevated cortisol accelerate bone loss, so stress reduction supports the same goal as strontium; strontium itself is not known to affect the stress-hormone axis in either direction.

Monitoring Protocol & Defining Success

Baseline assessment before starting strontium should establish bone status, exclude the conditions that make it unsafe, and set reference values; because strontium distorts bone-density scans, the baseline DXA is especially important for later interpretation. Ongoing monitoring then tracks safety and the trend rather than relying on any single inflated density figure.

Ongoing monitoring cadence: reassess kidney function and clinical clot/cardiovascular status at roughly 3–6 months after starting and then every 6–12 months, repeat DXA at 12–24 months interpreted with the strontium artefact in mind, and review continued need at least yearly.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Bone mineral density (DXA T-score) Trend upward; T-score above -2.5 Tracks the core bone target Readings are inflated by strontium (about half the gain is artefactual); judge trend, not absolute jump; same scanner ideal
Estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73m² Strontium is kidney-cleared; guards against accumulation Below 30 mL/min favors avoidance; fasting not required
Serum calcium 8.6–10.0 mg/dL (mid-range) Ensures calcium sufficiency and detects imbalance Strontium can interfere with some calcium assays; interpret with the lab’s method in mind
25-hydroxyvitamin D 40–60 ng/mL Vitamin D repletion is needed for bone benefit Correct deficiency before relying on strontium; best drawn any time, not fasting-dependent
C-terminal telopeptide (CTX, a bone-breakdown marker) Lower half of reference range Gauges bone-resorption activity and response Fasting morning draw preferred; pairs well with a bone-formation marker (P1NP)
High-sensitivity C-reactive protein (hs-CRP, an inflammation marker) < 1.0 mg/L Contextual cardiovascular-risk marker given heart-safety concerns Not strontium-specific; supports overall risk monitoring; avoid testing during acute illness

Qualitative markers of success and safety to self-track:

  • Absence of new fractures or height loss over time
  • No leg swelling, calf pain, chest pain, or breathlessness (possible clot warning signs)
  • No widespread rash or unexplained fever, especially early in treatment
  • Stable digestion without persistent diarrhea or nausea
  • General mobility, strength, and energy maintained or improved

Emerging Research

Emerging work is framed for a reader deciding whether strontium’s evidence is likely to strengthen or weaken; current active trials mostly involve local, material-science uses rather than new systemic supplementation, and much of the informative recent evidence concerns safety.

  • Strontium bioactive glass for root caries (ongoing): A large controlled trial of fluoride varnish fortified with strontium-containing bioactive glass-ceramic for preventing root cavities. NCT06131957 — 540 participants, University of Hong Kong, evaluating new root-caries lesions.

  • Strontium-doped adhesive for dentine hypersensitivity (planned): A controlled trial testing a dentine adhesive containing strontium-doped bioactive glass-ceramic for tooth sensitivity. NCT07628712 — 142 participants, University of Hong Kong, primary outcome a sensitivity score.

  • Strontium-hydroxyapatite-coated mini-screws (recruiting): A study of strontium-hydroxyapatite-coated orthodontic mini-screws assessing antibacterial effect and stability, illustrating strontium’s move into implant coatings. NCT07105969 — 20 participants, Mansoura University.

  • Cardiovascular-safety re-evaluation (evidence that could weaken the case): Large multi-database pharmacoepidemiology continues to probe the clot and heart signals; a five-country study found excess venous clots and cardiovascular death but no clear heart-attack excess. Ali et al., 2020 informs whether restrictions should tighten or ease.

  • Reassessment of the heart-attack signal (evidence that could strengthen the case): A narrative synthesis argues the myocardial-infarction concern may be weaker than first thought once confounding is addressed, supporting continued restricted use. Curtis et al., 2021 reviews this landscape, complemented by a cohort finding no acute-coronary excess. Svanström et al., 2014.

  • Open question — supplement-form safety and bone quality: The most consequential future research areas are controlled long-term safety of strontium citrate and whether strontium produces true bone-quality gains, since recent bone-material analyses suggest it may not, which would reframe its density benefit.

Conclusion

Strontium is a calcium-like mineral that concentrates in bone, available both as a restricted prescription salt and as a widely sold supplement. Its best-supported benefit is fewer spine fractures in women with established bone loss, together with clear rises in bone-density readings. Both findings carry important caveats: a meaningful part of the density gain is a measurement effect of the mineral rather than genuine new bone, and benefits outside the spine are more modest and less certain. The safety record is what most shapes strontium’s standing. Blood clots are the most consistent serious harm, rare but severe allergic reactions can occur, and a possible increase in heart attacks remains genuinely disputed, with some large real-world studies finding no such effect. These concerns led regulators to limit the drug to severe cases in people without heart or clotting risk, while the cheaper supplement form remains far less tested. The evidence base is moderate in quality for the prescription salt and thin for the supplement, and it is complicated by commercial interests on both sides — the manufacturer, Servier, funded the pivotal efficacy trials, while sellers promote the cheaper supplement form. For someone weighing strontium, the picture is one of a real but bounded bone benefit set against uncertain but potentially serious risks, best judged individually rather than assumed either safe or effective.

Top - Benefits - Risks - Protocol